NCT03577301 (YMHP) is a NA clinical trial of Clinic-based Delivery in HIV Infections, sponsored by Florida State University.

Who is sponsoring NCT03577301?

NCT03577301 is sponsored by Florida State University.

What drugs are being tested in NCT03577301?

Interventions in NCT03577301: Clinic-based Delivery, Remote Delivery, Multi-modal Delivery.

What condition does NCT03577301 study?

NCT03577301 studies HIV Infections.

Is NCT03577301 still recruiting?

NCT03577301 is currently completed. Last updated 3 September 2024.

Are results published for NCT03577301?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2024-09-03 · How we verify

NCT03577301: YMHP

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Young Men's Health Project Targeting HIV Risk Reduction and Substance Abuse

Completed NA Results posted Last updated 3 September 2024

What this trial tests

NA trial testing Clinic-based Delivery in HIV Infections in 83 participants. Completed in 31 May 2022.

Timeline

4 October 2018

Primary endpoint
31 May 2022

31 May 2022

Quick facts

Lead sponsor	Florida State University
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	prevention
Enrollment	83
Start date	4 October 2018
Primary completion	31 May 2022
Estimated completion	31 May 2022
Sites	3 locations across United States

Drugs / interventions tested

Clinic-based Delivery
Remote Delivery
Multi-modal Delivery

Conditions studied

HIV Infections — all drugs for HIV Infections →

Sponsor

Florida State University

Who can join

Adults 15 to 24, male only, with HIV Infections. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Illicit Drug Use Days Primary · baseline, 3 months, 6 months, 9 months, 12 months

The self-reported number of illicit drug use days (not including marijuana) in the past 30 days

Use at Baseline

Group	Value	95% CI
Clinic-based Delivery	3.17	± 4.10
Remote Delivery	3.10	± 7.37
Multi-modal Delivery	3.25	± 5.99
Treatment as Usual	2.86	± 6.76

Use at 3 Months

Group	Value	95% CI
Clinic-based Delivery	9.00	± 19.16
Remote Delivery	5.12	± 10.89
Multi-modal Delivery	2.55	± 5.66
Treatment as Usual	9.21	± 29.62

Use at 6 Months

Group	Value	95% CI
Clinic-based Delivery	9.64	± 24.38
Remote Delivery	5.93	± 16.04
Multi-modal Delivery	3.23	± 9.03
Treatment as Usual	2.64	± 6.17

Use at 9 Months

Group	Value	95% CI
Clinic-based Delivery	1.58	± 3.70
Remote Delivery	3.46	± 8.35
Multi-modal Delivery	7.45	± 23.09
Treatment as Usual	10.93	± 34.99

Use at 12 Months

Group	Value	95% CI
Clinic-based Delivery	9.91	± 27.70
Remote Delivery	3.80	± 9.27
Multi-modal Delivery	1.00	± 1.89
Treatment as Usual	1.33	± 1.21

Condomless Anal Sex Acts Primary · baseline, 3 months, 6 months, 9 months, 12 months

The self-reported number of condomless anal sex acts with male partners in the last 30 days prior to assessment point.

Baseline

Group	Value	95% CI
Clinic-based Delivery	5.9	± 4.91
Remote Delivery	4.5	± 8.6
Multi-modal Delivery	6.9	± 8.98
Treatment as Usual	10.0	± 14.54

3 Month

Group	Value	95% CI
Clinic-based Delivery	3.1	± 4.44
Remote Delivery	5.9	± 12.81
Multi-modal Delivery	6.8	± 10.20
Treatment as Usual	10.2	± 20.20

6 Month

Group	Value	95% CI
Clinic-based Delivery	5.4	± 8.18
Remote Delivery	4.4	± 10.57
Multi-modal Delivery	8.9	± 13.74
Treatment as Usual	10.6	± 23.93

9 Month

Group	Value	95% CI
Clinic-based Delivery	11.0	± 14.75
Remote Delivery	13.6	± 30.07
Multi-modal Delivery	13.2	± 18.19
Treatment as Usual	20.6	± 48.34

12 Month

Group	Value	95% CI
Clinic-based Delivery	10.8	± 18.30
Remote Delivery	2.3	± 5.58
Multi-modal Delivery	11.9	± 16.98
Treatment as Usual	1.2	± 1.30

Marijuana Use Days Primary · baseline, 3 months, 6 months, 9 months, 12 months

The self-reported number of marijuana use days in the past 30 days prior to assessment point.

Baseline

Group	Value	95% CI
Clinic-based Delivery	31.38	± 34.01
Remote Delivery	34.09	± 38.48
Multi-modal Delivery	32.00	± 35.40
Treatment as Usual	19.00	± 29.30

3 Month

Group	Value	95% CI
Clinic-based Delivery	40.00	± 37.21
Remote Delivery	32.75	± 36.56
Multi-modal Delivery	26.00	± 32.66
Treatment as Usual	20.16	± 28.71

6 Month

Group	Value	95% CI
Clinic-based Delivery	41.71	± 38.43
Remote Delivery	32.57	± 35.67
Multi-modal Delivery	28.77	± 32.72
Treatment as Usual	19.50	± 28.25

9 Month

Group	Value	95% CI
Clinic-based Delivery	42.00	± 41.60
Remote Delivery	33.08	± 35.44
Multi-modal Delivery	22.27	± 30.05
Treatment as Usual	24.71	± 34.73

12 Month

Group	Value	95% CI
Clinic-based Delivery	41.82	± 36.61
Remote Delivery	37.20	± 38.60
Multi-modal Delivery	34.80	± 38.01
Treatment as Usual	18.50	± 24.07

Alcohol Use Days Secondary · baseline, 3 months, 6 months, 9 months, 12 months

The self-reported number of alcohol use days in the past 30 days

Baseline

Group	Value	95% CI
Clinic-based Delivery	20.17	± 17.82
Remote Delivery	13.71	± 15.35
Multi-modal Delivery	17.62	± 20.03
Treatment as Usual	17.27	± 15.22

3 Month

Group	Value	95% CI
Clinic-based Delivery	20.60	± 17.52
Remote Delivery	12.06	± 12.54
Multi-modal Delivery	13.45	± 13.57
Treatment as Usual	16.89	± 15.49

6 Month

Group	Value	95% CI
Clinic-based Delivery	18.78	± 18.63
Remote Delivery	9.78	± 10.49
Multi-modal Delivery	10.15	± 11.01
Treatment as Usual	17.36	± 15.96

9 Month

Group	Value	95% CI
Clinic-based Delivery	15.00	± 14.34
Remote Delivery	14.61	± 15.84
Multi-modal Delivery	13.27	± 17.27
Treatment as Usual	17.43	± 14.05

12 Month

Group	Value	95% CI
Clinic-based Delivery	20.91	± 23.34
Remote Delivery	13.50	± 22.15
Multi-modal Delivery	22.33	± 18.49
Treatment as Usual	15.30	± 23.76

Sponsor's own description

YMHP is a counseling intervention program for which the goals are to better understand HIV-prevention focused self-management behaviors among HIV-negative YMSM, and to study the implementation of YMHP to improve portability and scalability. The clinic sites will help investigators to assess and address practical problems at the frontline of service provision to pave the way for a comprehensive program to reduce HIV infection among YMSM that reflects the complexities of real world adolescent HIV clinics.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for HIV Infections

Currently open trials in the same condition.

NCT07225530 — Implementation of Screen, Treat, and Triage for Women Living With HIV in La Romana (iSTAR) · NA · recruiting
NCT07202546 — A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study) · Phase 2 · recruiting
NCT06694753 — Safety and Immunogenicity Study of Three mRNAs Encoding HIV Immunogens in Adult Participants Without HIV and in Overall · Phase 1 · recruiting
NCT07235852 — Pilot Testing Into the Feasibility of the Developed Cognitive Behavioral Therapy Intervention · NA · recruiting
NCT06665646 — Clinical Trial to Evaluate the Safety and Immunogenicity of Hiltonol, Poly-ICLC-adjuvanted CD40.HIVRI.Env (VRIPRO) in Ad · Phase 1 · recruiting

Other Florida State University trials

Trials by the same sponsor.

NCT06127914 — Learning Early Infant Feeding Cues · NA · not yet recruiting
NCT06015581 — Scaling Up Implementation Strategies to Improve the DIAGNOSE and PREVENT Pillars for Young MSM in Florida · NA · not yet recruiting
NCT07467473 — Causal Role of Rostromedial Prefrontal Cortex for Positive Savoring in Depression · NA · enrolling by invitation
NCT07221448 — Sodium vs Potassium Education to Improve Vascular Health · NA · recruiting
NCT07415941 — MBM and taVNS for Low Back Pain and Depressive Symptoms · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03577301 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Florida State University
Last refreshed: 3 September 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03577301.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing

NCT03577301: YMHP

Quick facts

Drugs / interventions tested

Conditions studied

Sponsor

Who can join

Results — posted to ClinicalTrials.gov

Sponsor's own description

Publications & conference data

Related trials

Other recruiting trials for HIV Infections

Other Florida State University trials

Verify against primary sources